Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America
and affects ca. 10 million people worldwide. About 30% of Chagas disease patients develop …

More than 100 years after the discovery of human American trypanosomiasis by Carlos
Chagas, our knowledge and management of the disease are profoundly changing …

The pathogenesis of Chagas disease cardiomyopathy (CCC) is not well understood. Since
studies show that myocarditis is more frequent during the advanced stages of the disease …

Perhaps one of the most intriguing aspects of human Chagas disease is the complex
network of events that underlie the generation of protective versus pathogenic immune …

Chagas disease, a neglected disease caused by the protozoan Trypanosoma cruzi, is
endemic in 21 Latin American countries, affecting 6–8 million people. Increasing numbers of …

This study was designed to determine whether the functional IL-10 gene polymorphism−
1082G/A is associated with the development of cardiomyopathy in individuals infected with …

Chagas disease continues to be a significant public health problem, as ca. 10 million people
are still infected with T. cruzi in Latin America. Decades after primary infection, 30% of …

Chagas disease is among the neglected tropical diseases recognized by the World Health
Organization that have received insufficient attention from governments and health …

RNA helicase enzymes catalyze the in vivo folding and conformational re-arrangement of
RNA. DEAD-box proteins (DBPs) make up the largest family of RNA helicases and are found …

Chagas' disease, caused by Trypanosoma cruzi infection, is ranked as the most serious
parasitic disease in Latin America. Nearly 30% of infected patients develop life-threatening …